Sigma-2 Receptor Neurons are neurons expressing the σ2 receptor (also known as TMEM97), a unique membrane protein that has drawn significant attention in neurodegenerative disease research. Originally identified as a distinct pharmacological entity separate from sigma-1 receptors, the σ2 receptor is now understood to be an integral membrane protein involved in multiple cellular processes including calcium homeostasis, lipid metabolism, autophagy, and cellular stress responses. These receptor neurons are widely distributed throughout the brain, with particularly high expression in the hippocampus, cerebral cortex, dorsal root ganglia, and basal ganglia, where they modulate neurotransmission and participate in cellular survival mechanisms. [@collinson2006][@maurovich2007]
The σ2 receptor is encoded by the TMEM97 gene located on chromosome 17q25.2 in humans. Unlike classical G protein-coupled receptors, the σ2 receptor appears to signal through multiple mechanisms including modulation of ion channels, interaction with the inositol 1,4,5-trisphosphate (IP3) receptor, and regulation of cholesterol homeostasis. The receptor has been shown to bind with high affinity to various synthetic ligands including SB-74114, SW120, and several imaging agents used in positron emission tomography (PET) studies. Research has demonstrated that σ2 receptor expression changes with age and in neurodegenerative conditions, making it a potential biomarker for disease progression. [@ishikawa2011][@rui2012]
Sigma-2 Receptor Neurons are neurons expressing the σ2 receptor (also known as TMEM97), a unique membrane protein that has drawn significant attention in neurodegenerative disease research. Originally identified as a distinct pharmacological entity separate from sigma-1 receptors, the σ2 receptor is now understood to be an integral membrane protein involved in multiple cellular processes including calcium homeostasis, lipid metabolism, autophagy, and cellular stress responses. These receptor neurons are widely distributed throughout the brain, with particularly high expression in the hippocampus, cerebral cortex, dorsal root ganglia, and basal ganglia, where they modulate neurotransmission and participate in cellular survival mechanisms. [@collinson2006][@maurovich2007]
The σ2 receptor is encoded by the TMEM97 gene located on chromosome 17q25.2 in humans. Unlike classical G protein-coupled receptors, the σ2 receptor appears to signal through multiple mechanisms including modulation of ion channels, interaction with the inositol 1,4,5-trisphosphate (IP3) receptor, and regulation of cholesterol homeostasis. The receptor has been shown to bind with high affinity to various synthetic ligands including SB-74114, SW120, and several imaging agents used in positron emission tomography (PET) studies. Research has demonstrated that σ2 receptor expression changes with age and in neurodegenerative conditions, making it a potential biomarker for disease progression. [@ishikawa2011][@rui2012]
Sigma-2 receptor expression in the brain exhibits a characteristic regional distribution pattern. High levels of σ2 receptor binding are found in the hippocampus, particularly in the CA3 region and dentate gyrus, areas critical for memory formation and highly vulnerable in Alzheimer's disease. The cerebral cortex shows moderate to high expression, with higher densities in layer 4 than in other cortical layers. In the basal ganglia, σ2 receptors are enriched in the striatum and substantia nigra pars reticulata. Dorsal root ganglia contain abundant σ2 receptors, reflecting their role in peripheral sensory processing. This widespread distribution suggests that σ2 receptor neurons participate in multiple neural circuits and may serve diverse physiological functions. [@smith2017][@rui2012]
The σ2 receptor plays a crucial role in regulating intracellular calcium dynamics. Studies have shown that σ2 receptor activation can modulate voltage-gated calcium channels and influence calcium release from endoplasmic reticulum stores through IP3 receptors. This modulation affects neuronal excitability and synaptic plasticity. In pathological conditions, dysregulation of calcium homeostasis is a hallmark feature of neurodegeneration, and σ2 receptors may represent a target for therapeutic intervention to restore proper calcium signaling. [@zhao2019]
The σ2 receptor has been implicated in cellular cholesterol homeostasis through interaction with the sigma-2 receptor-associated protein (S2RAP), which also binds to the LDL receptor-related protein 1 (LRP1). This interaction influences cholesterol trafficking and may affect amyloid precursor protein (APP) processing. Given the central role of cholesterol dysregulation in Alzheimer's disease pathogenesis, σ2 receptor-mediated pathways represent a potential therapeutic target for modulating lipid metabolism in neurodegeneration. [@ishikawa2011]
Sigma-2 receptor activation has been shown to induce autophagy in neuronal cells through mechanisms involving the AMPK-mTOR signaling pathway. Autophagy is essential for clearing misfolded proteins and damaged organelles, processes that are impaired in most neurodegenerative diseases. The σ2 receptor can also modulate endoplasmic reticulum stress responses and influence the unfolded protein response (UPR), which is activated in neurons accumulating misfolded proteins. [@liu2016][@yoshida2018]
In Alzheimer's disease (AD), σ2 receptor expression is significantly altered in brain regions affected by pathology. Post-mortem studies have demonstrated increased σ2 receptor binding in the prefrontal cortex and hippocampus of AD patients compared to age-matched controls, potentially reflecting reactive glial changes and neuronal stress responses. Importantly, σ2 receptor agonists have been shown to protect against amyloid-beta (Aβ)-induced toxicity in neuronal cell cultures and animal models. These protective effects involve reduced caspase activation, decreased oxidative stress, and improved mitochondrial function. The mechanism appears to involve modulation of cellular stress pathways and enhancement of autophagy-mediated clearance of toxic Aβ aggregates. [@zhao2019][@kim2018][@cottrell2021]
While less extensively studied than in AD, σ2 receptor alterations have been reported in Parkinson's disease (PD) models. The receptor may modulate dopaminergic neuron survival through effects on mitochondrial function and cellular stress resistance. Sigma-2 receptor ligands have shown promise in protecting against 1-methyl-4-phenylpyridinium (MPP+)-induced toxicity in dopaminergic cell lines, suggesting potential therapeutic applications in PD. [@smith2017]
Sigma-2 receptors are expressed in retinal ganglion cells and photoreceptors, where they participate in maintaining neuronal survival under conditions of oxidative stress. Studies in animal models of retinal degeneration have demonstrated that σ2 receptor agonists can protect against light-induced photoreceptor death and preserve retinal function. These findings suggest potential applications for σ2 receptor-targeted therapies in neurodegenerative conditions affecting the visual system. [@tesar2020]
Sigma-2 receptor neurons are critically involved in regulating mitochondrial function. The σ2 receptor localizes to mitochondrial membranes and influences mitochondrial calcium uptake, membrane potential, and reactive oxygen species (ROS) production. In neurons undergoing metabolic stress or excitotoxicity, σ2 receptor activation can help maintain mitochondrial homeostasis and prevent cell death. This neuroprotective effect involves modulation of the mitochondrial permeability transition pore (mPTP) and regulation of apoptosis-related proteins. Studies have shown that σ2 receptor ligands can preserve ATP levels and prevent mitochondrial depolarization under pathological conditions, making these receptors attractive targets for maintaining neuronal energy metabolism in neurodegeneration. [@espadas2020][@vanwaarde2010]
The unique binding properties of σ2 receptors have enabled development of PET radiotracers for imaging σ2 receptor density in vivo. These imaging agents can potentially serve as biomarkers for detecting neuronal loss, monitoring disease progression, and evaluating treatment responses in neurodegenerative diseases. Several σ2 receptor-selective PET tracers have been validated in preclinical models and are being evaluated in human studies for their utility in AD and other conditions. [@chen2022]
Small molecule σ2 receptor agonists and antagonists are being developed for neuroprotective applications. The goal is to identify compounds that can enhance endogenous protective pathways without causing adverse effects. Key considerations include receptor subtype selectivity, brain penetration, and appropriate pharmacokinetic properties. Several lead compounds have shown promise in preclinical models of AD and PD, and some have advanced to early-stage clinical trials. [@george2021][@cottrell2021]
Sigma-2 receptor neurons exhibit functional interactions with several other receptor systems relevant to neurodegeneration. The σ2 receptor can modulate NMDA receptor function and influence glutamatergic neurotransmission, which is important given the excitotoxic mechanisms implicated in multiple neurodegenerative conditions. Additionally, σ2 receptors interact with the sigma-1 receptor, forming heteromeric complexes that may have distinct pharmacological properties. Understanding these receptor interactions is important for developing combination therapies that target multiple pathways simultaneously.
Despite significant progress, several challenges remain in understanding σ2 receptor biology and developing effective therapeutics. The lack of a known endogenous ligand has complicated studies of physiological function. Additionally, the receptor's complex signaling mechanisms and tissue-specific effects require careful characterization. Future research directions include: (1) identifying endogenous σ2 receptor ligands, (2) determining the crystal structure to enable rational drug design, (3) developing more selective and brain-penetrant ligands, and (4) conducting clinical trials to validate σ2 receptors as therapeutic targets in human neurodegenerative diseases. The integration of PET imaging with biomarker studies will be crucial for advancing this field.